Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

NCT05810142 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05810142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05810142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab
Lead sponsor
RenJi Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
July 1, 2023
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dvanced duodenal adenocarcinoma, furquinelone combined with sintilimab, third-line treatment